Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study
Open Access
- 21 February 2018
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 31 (6) , 639-648
Abstract
Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyclovir-resistant HSV by plaque reduction test who received an HCT from 2002 through 2014. A total of 4 028 HCTs were performed during the study period, and 18 of the recipients met the diagnostic criteria for acyclovir-resistant HSV. All cases had undergone allogeneic HCTs. Most patients were in the pre-engraftment period or on systemic corticosteroid therapy for graft-versus-host disease (GVHD). The median time between diagnosis and susceptibility testing was 15 days, and antiviral therapy was changed at a median of 27 days. Patients required prolonged therapy (~80 days), and many had serious complications including renal failure and hospitalization. In conclusion, acyclovir-resistant HSV infection is more likely during the period of profound deficit in T-cell-mediated immunity and is associated with significant morbidities. Higher doses of acyclovir prophylaxis might be needed for patients with history of HSV during pre-engraftment or GVHD treatment. In patients who do not respond or progress after 1 week of acyclovir therapy, testing for drug-resistant HSV, and early switch to an alternative antiviral should be considered.Keywords
Funding Information
- National Institutes of Health
This publication has 37 references indexed in Scilit:
- Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibodyProceedings of the National Academy of Sciences, 2013
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2011
- Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and ManagementAntimicrobial Agents and Chemotherapy, 2011
- Treatment of Acyclovir-Resistant Herpes Simplex Virus with Continuous Infusion of High-Dose Acyclovir in Hematopoietic Cell Transplant PatientsTransplantation and Cellular Therapy, 2011
- Hematopoietic Stem Cell TransplantationA Global PerspectiveJAMA, 2010
- Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantationBest Practice & Research Clinical Haematology, 2008
- Frequency of acyclovir‐resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndromeInternational Journal of Dermatology, 2007
- Antiviral therapy of HSV-1 and -22007
- Resistant Herpes Simplex Virus Type 1 Infection: An Emerging Concern after Allogeneic Stem Cell TransplantationClinical Infectious Diseases, 2000
- Resistance to Antiviral Drugs in Herpes Simplex Virus Infections among Allogeneic Stem Cell Transplant Recipients: Risk Factors and Prognostic SignificanceThe Journal of Infectious Diseases, 2000